Onderzoeksgrade Sotigalimab

TheFDAhasgrantedanorphandrugdesignationtosotigalimab (APX005M) asapotentialtherapeuticoptionforpatientswithsofttissuesarcoma, accordingtoannouncementfromApexigenInc., thedrugdeveloper. Anovel, humanizedmonoclonalantibody, sotigalimabwasdesignedstimulateantitumorimmuneresponseandtotargetCD40, whichisakeyco-stimulatoryreceptorthatservestoactivateinnateandadaptiveimmunesystems.WhensotigalimabbindstoCD40onantigen-presentingcells, itinducesamultifacetedimmuneresponsethatbringsseveralcomponentsoftheimmunesystemtogethertoattackthecancer.

APX005M, APX-005, APX-005-M, APX-005M, CAS:2305607-45-6

Mammalian Cells

Tumornecrosisfactorreceptorsuperfamilymember5, B-cellsurfaceantigenCD40, Bp50, CD40Lreceptor, TNFRSF5, CDw40, CD40

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Protein A/G purified from cell culture supernatant.

1.7mg/ml

Please contact with the lab for this information.

>95% as determined by SDS-PAGE.

Liquid

0.01M PBS, pH7.4.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at4°C short term (1-2weeks) . Store at-20°C 12 months. Store at -808°C long term.

For research use only. Not suitable for clinical or therapeutic use.

0.01M PBS, pH7.4.

Human

IgG1-Kappa